Gabion Technologies IPO Books 768x, GMP Signals Strong Listing Gain

IPO
Whalesbook Logo
AuthorVihaan Mehta|Published at:
Gabion Technologies IPO Books 768x, GMP Signals Strong Listing Gain
Overview

Gabion Technologies IPO saw an overwhelming 768x subscription, with retail and NII portions soaring. Trading at a ₹32 premium (39.51%) in grey markets, the issue is poised for a strong debut on the BSE SME platform on January 12, 2026. Allotment status is expected today, January 9, 2026.

IPO Closes with Record Subscription

Gabion Technologies' Initial Public Offering (IPO) concluded on January 8, 2026, achieving an extraordinary subscription level of 768.12 times its offered shares. The ₹29.16 crore public issue is set to finalize its basis of allotment today, January 9, 2026.

Unprecedented Investor Demand

The IPO witnessed massive participation across all investor categories. Non-institutional investors (NIIs) led the charge, oversubscribing their reserved portion by an exceptional 1,085.88 times. Retail investors followed closely, applying for 867.21 times their allocated shares. Qualified institutional buyers (QIBs), while showing comparatively less, still subscribed their portion a significant 271.13 times.

The offering was priced within a band of ₹76 to ₹81 per share, with a lot size of 1,600 shares. A total of 1,97,99,16,800 shares were bid for against the 25,77,600 shares made available to the public.

Strong Listing Prospects Amidst High GMP

Gabion Technologies shares are commanding a substantial premium in the grey market. As of Friday, January 9, 2026, unlisted shares traded around ₹113, reflecting a grey market premium (GMP) of ₹32 per share. This represents a robust 39.51% premium over the issue's upper price band of ₹81.

Scheduled to list on the BSE SME platform on January 12, 2026, current grey market trends suggest a strong debut. If the current GMP holds, investors could see returns exceeding 39% on listing day. However, it is crucial to note that the grey market is unregulated and these premiums are not always indicative of actual market performance.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.